Costs for patients treated with olaparib, enzalutamide, or abiraterone increased substantially in the subgroup of patients with a tumor harboring at least one of three prespecified gene alterations (BRCA1, BRCA2, or ATM) versus those with at least one of 15 prespecified gene alterations (Table 5). The gene discussed is ATM; the disease is neoplasm.